With nearly 50 products and solutions, Philips spotlights AI-driven future of health at 8th CIIE

On November 5, 2025, Philips, a global leader in health technology, made its eighth appearance at the China International Import Expo (CIIE). Under the theme "Innovation with Purpose, Caring for All," the company showcased nearly 50 innovative products and solutions spanning precision diagnosis and therapy, smart intervention and imaging, and personal health. The display included ten "China debut" products and over ten AI-enabled health technology solutions.

As a global health technology enterprise with 40 years of deep-rooted presence in China, Philips centered its CIIE booth around the "Full Journey of Health Care," showcasing AI-enabled clinical innovations across medical imaging, smart interventional navigation, and critical care. The display focused on AI's in-depth application in assisted diagnosis, workflow optimization, and reducing the medical workforce burden.

For healthcare institutions, the integration of AI imaging algorithms with intelligent connected platforms enables physicians to achieve earlier and more precise diagnosis and treatment. For patients, products like smart respiratory management and AI-powered oral care extend health management to the home setting, advancing the shift from "treating diseases" to "preventing diseases." Furthermore, targeting major conditions prevalent in China—such as cardiovascular diseases, cancer, and stroke—Philips leverages its strength in integrating imaging and AI to build end-to-end solutions covering screening, diagnosis, treatment, and follow-up. These solutions are already successfully implemented in multiple hospitals across China, supporting clinicians in delivering precise, efficient, and safe care.

As China accelerates the development of its "AI+Healthcare" system, trust and value in AI have become central industry concerns. Philips, leveraging both global expertise and local insights, is actively advancing the practical application of AI in healthcare trust, clinical validation, and value creation.

During the 8th CIIE, Philips will officially release the China edition of its Future Health Index 2025 Report. This report, based on a global survey covering over 1,900 healthcare professionals and 16,000 patients across 16 countries and regions, provides an in-depth analysis of AI's critical role in improving efficiency, reducing burdens, and enabling proactive health management. The findings reveal that Chinese patients' trust in AI healthcare ranks among the highest globally, with the industry rapidly building a safer, more transparent, and people-centric smart healthcare ecosystem.

Currently, nearly half of Philips' approximately €1.7 billion annual R&D investment is dedicated to AI and data science, with nearly 1,000 related patents filed. By deeply integrating AI into clinical workflows, Philips continues to enhance diagnostic efficiency and improve health outcomes through intelligent tools. The company is also actively participating in industry standard-setting and cross-sector collaboration, working with Chinese partners to drive the digital transformation of the healthcare system.

Since establishing its first joint venture in China in 1985, Philips has become a trusted long-term partner in China's healthcare industry. The company has developed comprehensive local capabilities spanning R&D, manufacturing, and services, supported by five innovation centers and five manufacturing bases across the country. Over 95% of Philips products available in China are now developed and manufactured locally. Today, China is not only Philips' second-largest market globally but also a pivotal hub for innovation and value creation.